These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25805597)

  • 1. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.
    Clarke JD; Cherrington NJ
    Pharmacol Ther; 2015 Jul; 151():99-106. PubMed ID: 25805597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.
    Montonye ML; Tian DD; Arman T; Lynch KD; Hagenbuch B; Paine MF; Clarke JD
    J Pharmacol Exp Ther; 2019 Nov; 371(2):385-393. PubMed ID: 31420525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.
    Lorbek G; Urlep Ž; Rozman D
    Pharmacogenomics; 2016 Jul; 17(11):1273-1288. PubMed ID: 27377717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease.
    Cespiati A; Youngson NA; Tourna A; Valenti L
    Curr Pharm Des; 2020; 26(10):998-1009. PubMed ID: 31969087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy.
    Bechtold B; Clarke J
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):397-412. PubMed ID: 33339463
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-alcoholic Steatohepatitis (NASH) Drug Discovery - Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development.
    Dash RP; Babu RJ; Srinivas NR
    J Pharm Pharm Sci; 2018; 21(1):481-495. PubMed ID: 30472977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.
    Canet MJ; Cherrington NJ
    Expert Opin Drug Metab Toxicol; 2014 Sep; 10(9):1209-19. PubMed ID: 24989624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
    Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
    Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
    Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
    Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
    Wree A; Mehal WZ; Feldstein AE
    Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.
    Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Goedken MJ; Cherrington NJ
    Drug Metab Dispos; 2015 Feb; 43(2):266-72. PubMed ID: 25488932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
    Delarue J; Lallès JP
    Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
    Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
    Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
    Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
    Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.
    Dongiovanni P; Romeo S; Valenti L
    Biomed Res Int; 2015; 2015():460190. PubMed ID: 26273621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
    Marie S; Frost KL; Hau RK; Martinez-Guerrero L; Izu JM; Myers CM; Wright SH; Cherrington NJ
    Acta Pharm Sin B; 2023 Jan; 13(1):1-28. PubMed ID: 36815037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease.
    Thrasher T; Abdelmalek MF
    N C Med J; 2016; 77(3):216-9. PubMed ID: 27154894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
    Lai Y; Varma M; Feng B; Stephens JC; Kimoto E; El-Kattan A; Ichikawa K; Kikkawa H; Ono C; Suzuki A; Suzuki M; Yamamoto Y; Tremaine L
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):723-43. PubMed ID: 22509796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.